Achieving Treatment Goals in Myelofibrosis with JAK Inhibitors and Emerging Therapies | PTCE Pharmacy Connect
Educational Objective: Outline the standard treatment options for myelofibrosis as well as review clinical data for Janus kinase inhibitors and emerging targeted therapies.
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan
Victoria Nachar, PharmD, BCOP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-396-H01-P. The activity is available for CE credit through August 29, 2023.
This activity is supported by an educational grant from Incyte Corporation.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan
Victoria Nachar, PharmD, BCOP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-396-H01-P. The activity is available for CE credit through August 29, 2023.
This activity is supported by an educational grant from Incyte Corporation.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Activity